BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

Rhea-AI Summary

BioSig Technologies (NASDAQ: BSGM) has provided clarification regarding its merger with Streamex Exchange Corporation and recent Schedule 14A filing. The merger, which closed on May 28, 2025, resulted in 19.99% of BioSig shares being issuable to Streamex shareholders, with remaining issuances pending NASDAQ approval.

The company announced that Proposal No. 1 (Acquisition Proposal) will be adjourned from the September 5, 2025 Special Meeting to a later date, awaiting final NASDAQ approval. This adjournment does not affect the merger closing, company operations, or ongoing financings. The remaining share issuances require formal stockholder approval at the reconvened Special Meeting.

Positive

• Merger with Streamex Exchange Corporation successfully closed on May 28, 2025
• 19.99% of shares already approved for issuance to Streamex shareholders
• Company operations and financings remain unaffected by the proxy adjournment

Negative

• Delay in obtaining final NASDAQ approval for remaining share issuances
• Postponement of Acquisition Proposal vote requiring additional shareholder meeting

Proposal No. 1 (The Acquisition Proposal) to be adjourned pending final NASDAQ approval; Company operations, financings and closing of the merger transaction remain not impacted

LOS ANGELES and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today provided an update regarding the status of the merger and related proxy materials.

The merger transaction closed on May 28, 2025, under the previously executed Share Purchase Agreement. As part of this transaction, 19.99% of BioSig shares are already issuable to Streamex shareholders, with the remaining issuances pending Nasdaq approval.

In connection with the Company’s Schedule 14A filings, the Board of Directors has determined that, due to pending Nasdaq approval, Proposal No. 1 (the Acquisition Proposal) will not be acted upon at the September 5, 2025, Special Meeting and will instead be adjourned to a later date to be announced by the Company at the Special Meeting.

While the merger with Streamex has already been consummated, the issuance of the remaining shares requires formal stockholder approval, which will be obtained at the reconvened Special Meeting.

Importantly, the removal of Proposal No. 1 from the proxy does not impact:

• The closing of the merger;
• The timing of closings of the Company’s financings; or
• The operations of the Company.
  

All other proposals outlined in the Company’s definitive proxy statement will proceed as planned at the September 5, 2025 Special Meeting.

About Streamex

Streamex is an RWA tokenization company building Institutional grade infrastructure to bring the gold and commodities market on chain, enabled by a gold denominated treasury and tokenization technology powering the modern commodities market. Streamex is a wholly owned subsidiary of BioSig Technologies, Inc.

About BioSig Technologies

BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP™ Platform that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the acquisition will be obtained, and whether we will be able to maintain compliance with Nasdaq’s listing criteria in connection with the acquisition and otherwise. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled “Risk Factors” in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.

Contacts

BioSig/Streamex Press & Investor Relations:

Adele Carey
Alliance Advisors Investor Relations
acarey@allianceadvisors.com

Henry McPhie
CEO of BioSig, Co-Founder of Streamex
contact@Streamex.com
https://www.streamex.com/
https://x.com/streamex

FAQ

What is the current status of BioSig's (BSGM) merger with Streamex Exchange Corporation?

The merger closed on May 28, 2025, with 19.99% of BioSig shares already issuable to Streamex shareholders. The remaining share issuances are pending NASDAQ approval.

How does the Schedule 14A filing adjournment affect BSGM's merger and operations?

The adjournment of Proposal No. 1 does not affect the merger closing, company financings, or operations. Only the formal stockholder approval for remaining share issuances is delayed.

When will BSGM's Special Meeting take place and what will be discussed?

The Special Meeting is scheduled for September 5, 2025. While Proposal No. 1 is adjourned, all other proposals from the definitive proxy statement will proceed as planned.

What percentage of BioSig (BSGM) shares are currently approved for issuance to Streamex shareholders?

Currently, 19.99% of BioSig shares are approved for issuance to Streamex shareholders, with the remaining portion pending NASDAQ approval.

Why is BioSig (BSGM) adjourning Proposal No. 1 from the Special Meeting?

The adjournment is due to pending NASDAQ approval for the remaining share issuances. The proposal will be voted on at a reconvened Special Meeting to be announced later.